<DOC>
	<DOCNO>NCT00606645</DOCNO>
	<brief_summary>An open-label , multi-dose , single-arm , Phase 1 dose escalation study XmAb®2513 conduct define MTD recommend dose ( ) study , determine safety tolerability , characterize PK immunogenicity , evaluate antitumor activity XmAb2513 patient HL ALCL ( non-cutaneous ) receive two prior therapeutic regimen . There intra-patient dose escalation .</brief_summary>
	<brief_title>Safety Study XmAb®2513 Treat Hodgkin Lymphoma Anaplastic Large Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<criteria>Diagnosed HL ALCL . Patients must receive two prior therapeutic regimen , one include hematopoietic cell transplant , either autologous allogeneic transplant . If hematopoietic cell transplant refuse , patient eligible receive transplant , patient still eligible participate trial patient receive two prior chemotherapy base regimen . Patients receive allogeneic transplant must relapse less 6 month transplant must least 200 day posttransplant prior enrollment , evidence GVHD Patients least one radiographically measurable site disease 1.5 cm large dimension . Patients must complete anticancer treatment &gt; 4 week prior enrollment . Patients must complete palliative corticosteroid therapy ( e.g . management Type B symptom ) &gt; 2 week prior enrollment . Patients must 18 year age . Required baseline laboratory data : Platelet count 80,000/mm3 ( patient must platelet transfusiondependent evidence maintenance platelet count 50,000/mm3 28 day prior enrollment without transfusion ) Absolute neutrophil count &gt; 1,500/mm3 Creatinine ≤ 1.5 time ULN ALT ( SGPT ) /AST ( SGOT ) ≤ 2.5 time upper limit normal ( ULN ) Total bilirubin ≤ 1.5 time ULN Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . Patients know HL ALCL involvement either leptomeningeal central nervous system . Patients require treatment oral intravenous corticosteroid oral intravenous immunosuppressive agent . Patients designated Class III IV New York Heart Association criterion . Patients history myocardial infarction stroke within last 6 month . Patients active infection eligible . This include patient require antiinfective treatment 4 week period prior enrollment . Patients prophylactic antiinfective agent eligible provide sign active infection . Patients know HIV , Hepatitis B , Hepatitis C positive . Patients history prior malignancy HL ALCL remission great 5 year , exception basal squamous skin carcinoma , cervical carcinoma situ biopsy , localized prostate cancer ( Gleason score &lt; 5 ) . Patients pregnant breastfeeding . Patients major surgery radiation therapy within four week prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>